4.5 Article

Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Hematology

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

Guadalupe Onate et al.

Summary: This study analyzed the impact of DNMT3A(mut) in FLT3-ITD subsets and found that DNMT3A(mut) did not modify the overall prognosis exerted by FLT3-ITD in AML-NPM1, despite delayed MRD clearance, possibly because of MRD-driven preemptive intervention.

BLOOD ADVANCES (2022)

Article Hematology

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia

Satoshi Wakita et al.

Summary: Mutations of CCAAT/enhancer-binding protein alpha (CEBPAmu) significantly impact the prognosis of acute myeloid leukemia (AML). Particularly, CEBPAmu in the basic leucine zipper domain (bZIP) is strongly associated with a favorable prognosis and can serve as a potent marker for AML prognosis. This finding has implications for treatment stratification and the development of targeted therapeutic approaches in CEBPA-mutated AML.

BLOOD ADVANCES (2022)

Article Hematology

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Doehner et al.

Summary: The 2010 and 2017 editions of the European LeukemiaNet recommendations for AML diagnosis and management are widely recognized. There have been major advances in our understanding of AML, including disease classification updates, improvements in genomic diagnostics, and the development of new therapeutic agents. This update includes a revised genetic risk classification, response criteria, and treatment recommendations.
Review Medicine, General & Internal

Significance of Gene Diagnosis in Acute Myeloid Leukemia with the Emergence of New Molecular Target Drug Treatment

Hiroki Yamaguchi

Summary: In this study, the effectiveness of molecular targeted drug treatment for AML patients was evaluated through gene diagnosis. Currently, many new drugs have been developed in Western countries, while there is still a disparity in drug availability in Japan. Therefore, stratifying the prognosis of each patient and implementing appropriate treatment is necessary.

JOURNAL OF NIPPON MEDICAL SCHOOL (2022)

Article Oncology

Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients

Heba Allah E. Abd Elrhman et al.

Summary: AML patients were classified into 8 groups based on genetic markers, with those having three DNMT3A/FLT3/NPM1 mutations showing a heavy disease burden. The presence of DNMT3A gene mutation alone or in combination with FLT3 and/or NPM1 mutations indicated a poor prognosis.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Article Medicine, General & Internal

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

R. M. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Medicine, General & Internal

Genomic Classification and Prognosis in Acute Myeloid Leukemia

Elli Papaemmanuil et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Article Medicine, General & Internal

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

Timothy J. Ley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Oncology

Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia

Felicitas Thol et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Article Medicine, General & Internal

DNMT3A Mutations in Acute Myeloid Leukemia.

Timothy J. Ley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Hematology

Analysis of NPM1 gene mutations in Chinese adults with acute myeloid leukemia

Lingzhi Yan et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)

Article Medicine, General & Internal

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

B Falini et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)